A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
Authors:
Open Access
- 15 November 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
Abstract
Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumorally at 106 PFU/mL on day 1 (cycle 1), 108 PFU/mL on day 22 (cycle 2), and 108 PFU/mL every 2 weeks thereafter (cycles ≥ 3). Nine patients were enrolled, 6 with only locoregional disease and 3 with both locoregional and distant disease. No patient completed the planned 10 cycles or achieved complete or partial response. The median number of cycles administered was 4 (range, 3–8). Seven patients withdrew prematurely because of uncontrolled disease progression, 1 withdrew after cycle 3 because of fatigue, and 1 withdrew after cycle 4 for reasons unrelated to study treatment. Median progression-free survival and overall survival were 77 days (95% CI, 63–NA) and 361 days (95% CI, 240–NA). Two patients received 8 cycles with clinically stable disease as the best response. The most common grade 2 or higher adverse event was injection site reaction (n = 7, 78%). Future studies could examine whether combining intratumoral T-VEC with concurrent systemic therapy produces better outcomes.Keywords
All Related Versions
Funding Information
- Amgen
- NIH/NCI through the Cancer Center Support Grant of The University of Texas MD Anderson Cancer Center (CA016672)
- the Morgan Welch Inflammatory Breast Cancer Research Program; a State of Texas Rare and Aggressive Breast Cancer Research Program Grant
This publication has 23 references indexed in Scilit:
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaJournal of Clinical Oncology, 2015
- Clinical Outcome of Isolated Locoregional Recurrence in Patients With Breast Cancer According to Their Primary Local TreatmentClinical Breast Cancer, 2014
- Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanomaJournal for ImmunoTherapy of Cancer, 2014
- Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trialThe Lancet Oncology, 2014
- Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in PatientsScience Translational Medicine, 2012
- A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating FactorClinical Cancer Research, 2006
- Herpes simplex virus 1 (HSV-1) for cancer treatmentCancer Gene Therapy, 2006
- ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Therapy, 2003
- Locoregionally recurrent breast cancer: incidence, risk factors and survivalCancer Treatment Reviews, 2001
- Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumorsProceedings of the National Academy of Sciences, 2000